Cost of Implementing a VBA for a Long-Term CAR T-cell Therapy

August 21st 2018

A ground-breaking paper that explores the cost of implementing a performance-based MEA at the hospital level for a long-term regenerative therapy over 10-years.

The Cell and Gene Therapy Catapult and Verpora have teamed to publish a new research paper on "Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy".  This research explores the process of executing a drug-leasing scheme for a hypothetical therapy in Acute Lymphoblastic Leukaemia and quantifies the cost of monitoring the scheme within a hospital setting.  The research bases itself upon a tailored market research survey constructed by Verpora and undertaken by senior pharmacists working in the UK National Health Service.

Omar Ali, Head of Payers Verpora said, "Whilst the concept of drug-leasing is not new, this is an original piece of research evaluating the feasibility of integrating such an innovative reimbursement model from top-to-bottom, from Government bodies through to provider physicians and pharmacy departments within a healthcare system. The data includes outcomes-based remission monitoring costs that are often missing from the health economic models submitted to payer organisations by manufacturers.  If healthcare systems want to provide access to curative cell and gene therapies, it is important that we take 360° view on the impact of these reimbursement models and how they play out with all healthcare stakeholders.  We believe provides a methodological framework from which manufacturers and payers can truly evaluating the real-world integration of these innovative pricing strategies, ultimately providing access to patients of cutting-edge therapies."

About the author

Nick Merryfield

Nick Merryfield

Executive Chair of the Verpora Group and global healthcare innovator aiming to help improve patient access to life-changing medicines at a value sustainable to all stakeholders.